abs357.txt	objectives		neoadjuvant	chemotherapy	(nact)	versus	primary	debulking	surgery(pds)	for	advanced	epithelial	ovarian	cancer	(aeoc)	remains	controversial	in	theunited	states	generalizability	of	existing	trial	results	has	been	criticizedbecause	less	aggressive	procedures	than	commonly	used	the	unitedstates	as	a	result	economic	evaluations	using	input	data	from	these	trials	maynot	accurately	reflect	costs	and	outcomes	associated	with	more	primarysurgery	an	ongoing	performing	weinvestigated	cost-effectiveness	cost-utility	nact	pds	aeoc	methods	decision	tree	model	was	constructed	to	estimate	differences	inshort-term	hypothetical	cohort	15	000	patients(us	annual	incidence	aeoc)	treated	over	1-year	timehorizon	medicare	payer	perspective	included	percancer-related	death	averted	life-years	quality-adjusted	(qalys)gained	base-case	probabilities	utilities	were	based	on	surgicalcomplications	related	or	interval	neoplasmstrial	analyses	assumed	equivalent	survival	threshold	analysisestimated	maximum	difference	that	would	beingcost-effective	at	$50	000/qaly	$100	willingness-to-pay	thresholds	probabilistic	sensitivity	analysis	characterize	uncertainty	compared	$142	million	costsavings	1098	fewer	cancer-related	deaths	1355	1715	qalysgained	making	it	dominant	treatment	strategy	all	insensitivity	remained	99	3%	simulations	neoadjuvantchemotherapy	cost-effective	000/qalywillingness-to-pay	if	2	7	1	4months	respectively	conclusions	short	term	is	cost-saving	improved	however	provides	longer-term	advantage	may	becost-effective	research	needed	role	patient	preferences	intradeoffs	between	quality	life
